10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Chicago-based ARCH Venture Partners has announced the closing of a $2.975 billion fund to invest in the creation, development and funding of early-stage biotech companies. 30 June 2022
Effective July 1, uninsured people living with diabetes in the USA be able to obtain one or multiple Sanofi insulins from the French pharma major’s Insulins Valyou Savings Program with a valid prescription for a total of $35 for a 30-day supply. Previously, the program offered a 30-day supply of Sanofi insulins for $99. 30 June 2022
The pharmaceutical industry is facing the prospect of an increase in disputes in the coming months. A combination of recent events such as the pandemic, the changes arising from Brexit and the war in Ukraine have all had an impact on supply lines. The energy crisis and other economic conditions are contributing to inflationary pressures across the board. 30 June 2022
US pharma giant Pfizer and German partner BioNTech announced a new vaccine supply agreement with the US government to support the continued fight against COVID-19. 30 June 2022
June 30, 2022
The cardiomyopathies market is set to grow from $1.6 billion in 2021 to $5.2 billion in 2031 across the seven major markets (7MM: USA, 5EU (France, Germany, Italy, Spain, and the UK), and Japan) at a compound annual growth rate (CAGR) of 12.4%. 30 June 2022
Privately-held US biotech Generian Pharmaceuticals has entered into a collaboration and exclusive license agreement with Japanese drug major Astellas Pharma’s Mitobridge unit, to discover and develop novel small molecules for undruggable therapeutic targets by using a proprietary drug discovery platform for diseases that have limited treatment options. 29 June 2022
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document recommending Rinvoq (upadacitinib), from US drugmaker AbbVie, as a treatment of moderate to severe atopic dermatitis (AD) for adults and young people aged 12 and over. 29 June 2022
The US Department of Health and Human Services (HHS) yesterday announced an enhanced nationwide vaccination strategy to mitigate the spread of monkeypox. 29 June 2022
Coronavirus vaccine developers have been busy updating their jabs in time for cold weather booster campaigns, but a panel of US Food and Drug Administration scientists has just thrown a wrench into the works. 29 June 2022
NewAmsterdam Pharma, a Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, and privately-held Italian Menarini Group have announced an exclusive license agreement for the commercialization of obicetrapib. 29 June 2022
Specialty pharmaceutical company Santhera Pharmaceuticals has announced a delay to the finalization of its New Drug Application (NDA) for vamorolone. 29 June 2022
German pharma major Bayer says that its Kerendia (finerenone) was recognized by the American Diabetes Association (ADA) Standards of Medical Care in Diabetes - 2022 with a new grade A recommendation for improving cardiovascular (CV) outcomes and reducing the risk of chronic kidney disease (CKD) progression in patients with CKD associated with type 2 diabetes (T2D). 29 June 2022
MiroBio, which is developing checkpoint agonists to treat autoimmune diseases, today announced the completion of a $97million (£80 million) Series B financing led by Medicxi. 29 June 2022
Along with the launch this morning of a new report on the pharmaceutical industry by the trade group European Federation of Pharmaceutical Industries and Associations, EFPIA director Nathalie Moll set out her experiences and views in a blog. 29 June 2022
AbbVie has presented Phase III results evaluating the safety, tolerability and efficacy of the investigational candidate ABBV-951 (foslevodopa/foscarbidopa) in advanced Parkinson’s disease. 28 June 2022
Switzerland-based Roivant Sciences, which has a long history of creating new companies, has now unveiled Priovant Therapeutics, this time in collaboration with US pharma giant Pfizer, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. 28 June 2022
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
Beijing’s InnoCare Pharma has announced encouraging Phase II results for its novel TYK2 inhibitor, ICP-488, aimed at treating moderate-to-severe plaque psoriasis. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
GSK has reached a settlement with 10 plaintiff firms, resolving 93% of the Zantac (ranitidine) product liability cases it faced in state courts across the USA. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for dasiglucagon. 10 October 2024
CMS released a Request for Information (RFI) and a sample list of prescription drugs that the agency preliminarily intends to include under the proposed Medicare $2 Drug List Model. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024